Umesh Shukla - Concepedia

Author

Umesh Shukla

Also Known As

Dr. Umesh Shukla, Shukla, Umesh, Shukla, Umesh A., U A Shukla, U Shukla, U. A. Shukla, U.A. Shukla, Umesh A Shukla, Umesh A. Shukla, Umesh Shukla

104

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Janssen (United States)Janssen (Belgium)Inserm

About

Umesh Shukla is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	20	836
2	Health Sciences	3	3	99
3	Biochemistry	3	3	55
4	Engineering	1	1	27
5	Biomolecular Engineering	1	1	27

Umesh Shukla

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment Ger‐Jan C.M. Sanderink, C. Guimart, Marie‐Laure Ozoux, Thrombosis Research UrologyRenal FunctionProphylactic DoseMedicineKidney Failure	2002	196
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers Ger‐Jan Sanderink, A. Le Liboux, Navin Jariwala, Clinical Pharmacology & Therapeutics	2002	182
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection Fabien Zoulim, Oliver Lenz, Joris Vandenbossche, Gastroenterology	2020	114
Coadministration of Nefazodone and Benzodiazepines Rashmi H. Barbhaiya, Umesh Shukla, Patricia D. Kroboth, Journal of Clinical Psychopharmacology	1995	97
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 Christophe Moreno, Christophe Hézode, Patrick Marcellin, Journal of Hepatology Experienced PatientsHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2015	81
Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study Douglas T. Dieterich, Jürgen K. Rockstroh, Chloe Orkin, Clinical Infectious Diseases	2014	67
Predictors of acute kidney injury post-cardiopulmonary bypass in children Sidharth Kumar Sethi, Deepak Goyal, Dinesh Kumar Yadav, Clinical and Experimental Nephrology PediatricsPediatric Cardiac SurgeryPediatric SurgeryAcute Kidney InjuryMedicine	2011	65
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson, The Lancet. Gastroenterology & hepatology Ide AnaloguesViral HepatitisMedicineImmunologyAntiviral Drug Development	2023	64
Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration Rashmi H. Barbhaiya, Umesh Shukla, Carol Gleason, Antimicrobial Agents and Chemotherapy Tissue PenetrationElimination Half-lifeBioanalysisSkin Blister FluidMedicine	1990	55
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection Harry L.A. Janssen, Jinlin Hou, Tarik Asselah, Gut	2023	53

Page 1